Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3 .

Mark J Levis Mehdi Hamadani Brent R LoganRichard J JonesAnurag K SinghMark R Litzow John R WingardEsperanza B PapadopoulosAlexander E Perl Robert J Soiffer Celalettin Ustun Masumi Ueda Oshima Geoffrey L Uy Edmund K WallerSumithra VasuMelham M Solh Asmita Mishra Lori S Muffly Hee-Je KimJan-Henrik MikeschYuho Najima Masahiro OnozawaKirsty ThomsonArnon Nagler Andrew H WeiGuido MarcucciNancy L GellerNahla HasabouDavid DelgadoMatt RosalesJason E Hill Stanley C GillRishita NuthethiDenise KingHeather WittsackAdam MendizabalSteven M Devine Mary M Horowitz Yi-Bin Chennull null

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.

Keyphrases

acute myeloid leukemia
randomized controlled trial
healthcare
systematic review
cell cycle arrest
tyrosine kinase
big data
allogeneic hematopoietic stem cell transplantation
machine learning
mesenchymal stem cells
signaling pathway
data analysis
cell therapy